Patient and treatment characteristics
| Patients, tumor and treatment characteristics | |
| Age (years), median (range) | 31 (19–61) |
| Gravida, n (%) | |
| G0 | 20 (45%) |
| >G1 | 21 (47%) |
| Histology, n (%) | |
| Squamous cell carcinoma | 27 (62%) |
| Adenocarcinoma | 16 (36%) |
| Adenosquamous | 1 (2%) |
| Stage (FIGO 2009), n (%) | |
| IA1 (+LVSI) | 18 (41%) |
| IA2 | 5 (11%) |
| IB1 | 21 (48%) |
| LVSI, n (%)* | |
| Yes | 18 (41%) |
| No | 24 (55%) |
| Depth of stromal invasion (mm), median (range) | 2.3 (0.3–8) |
| Pathologic tumor size (mm), median (range) | 7.5 (0.8–25) |
| Diagnostic procedure, n (%)* | |
| Biopsy | 4 (9%) |
| LEEP | 18 (41%) |
| Cone | 21 (48%) |
| Margins at diagnostic procedure, n (%) | |
| Positive | 24 (54%) |
| Negative | 17 (39%) |
| Unknown | 3 (7%) |
| Residual disease on cone biopsy, n (%) | |
| Yes | 12 (28%) |
| No | 31 (70%) |
| No repeat cone | 1 (2%) |
| Lymph node assessment, n (%) | |
| SLN alone | 41 (93%) |
| SLN + ipsilateral pelvic lymphadenectomy | 1 (2%) |
| SLN + ipsilateral pelvic and para-aortic lymphadenectomy | 2 (5%) |
| Lymph node status, n (%) | |
| Negative | 41 (93%) |
| Positive (micrometastasis) | 3 (7%) |
| Adjuvant treatment, n (%) | |
| Yes (chemoradiation) | 2 (5%) |
| No | 42 (95%) |
| Completion surgery, n (%) | |
| Yes | 4 (9%) |
| For positive margins | (2 radical hysterectomy, 1 radical trachelectomy, 1 simple hysterectomy) |
| For cervical stenosis | 3 (7%) |
| For recurrent persistent HSIL | 1 (2%) |
| No | 36 (82%) |
*Missing 3 gravidity, 3 parity, 8 grade, 2 LVSI, 1 diagnostic procedure.
HSIL, high grade squamous intra-epithelial lesion; LEEP, loop electrosurgical excision procedure; LVSI, lymphovascular space invasion; SLN, sentinel lymph node.